Advanced Biomedical Research
The Investigation of Insulin Resistance in Two Groups of Epileptic Patients Treated with Sodium Valproate and Carbamazepine
Authors
- Mohammad Reza Najafi 1
- Bahareh Bazooyar 2
- Mohammad Zare 1
- Mohammad Reza Aghaghazvini 3
- Behnaz Ansari 1
- Ali Rajaei 1
- Masoumeh Dashti 1
1 Department of Neurology, Isfahan Neurosciences Research Center, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Internal Medicine, Babol University of Medical Sciences, Babol, Iran
3 Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Background: Valproic acid (VPA) is a widely used broad-spectrum antiepileptic drug for therapy of generalized and focal epilepsies. Cross-sectional studies have suggested that valproate treatment may be associated with hyperinsulinemia. We decided to investigate hyperinsulinemia as a health-threatening side effect of VPA in Iranian epileptic patients. Materials and Methods: Body mass index (BMI), lipid profile, fasting serum insulin, fasting blood glucose (FBS), and homeostatic model assessment-insulin resistance (HOMA-IR) were measured in 30 VPA-treated epileptic patients and 30 controls (CBZ-treated). The Chi-square test, t-test, and Pearson correlation test were used. Results: BMI was higher in VPA group than in control group (25.7 ± 3.5 > 21.7 ± 4.1) (0.000 < 0.05). Prevalence of obesity was 16.6% in VPA group that was almost the same and even lower than general Iranian population. Serum triglyceride (TG) (150 ± 77.2) was higher than CBZ group (114 ± 35.2) (P = 0.023 < 0.05). However, serum high-density lipoprotein level was lower in VPA group than controls (45.2 ± 11.7 < 54.4 ± 13.9) (P = 0.008 < 0.05). Serum insulin, FBS, HOMA-IR, cholesterol, and low-density lipoprotein did not demonstrate statistically significant differences between the two groups (P > 0.05). Conclusion: Despite the majority of previous studies that are against VPA and according to our study, VPA could be prescribed safely and it may not cause IR and its complications.
Keywords
| 1. |
Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72.  |
| 2. |
Burea M, Genton B, Dravet C, Delgado-Escueta A, Tassinari CA, Thomas P, et al. Epileptic syndromes in infancy, childhood and adolescence - With Videos (English and French Edition). London: Libbey; 1992. p. 313-27. |
| 3. |
Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No 264 Group. N Engl J Med 1992;327:765-71. |
| 4. |
Rättyä J, Vainionpää L, Knip M, Lanning P, Isojärvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-93. |
| 5. |
Jallon P, Picard F. Bodyweight gain and anticonvulsants: A comparative review. Drug Saf 2001;24:969-78. |
| 6. |
Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:265-8. |
| 7. |
Klein KM, Hamer HM, Reis J, Schmidtke J, Oertel WH, Theisen FM, et al. Weight change in monozygotic twins treated with valproate. Obes Res 2005;13:1330-4. |
| 8. |
El-Khatib F, Rauchenzauner M, Lechleitner M, Hoppichler F, Naser A, Waldmann M, et al. Valproate, weight gain and carbohydrate craving: A gender study. Seizure 2007;16:226-32. |
| 9. |
Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 1996;14:329-42. |
| 10. |
Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, et al. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism 1992;41:666-70. |
| 11. |
Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllylä VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84. |
| 12. |
Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed) 1981;283:577-81. |
| 13. |
Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can J Neurol Sci 1997;24:240-4. |
| 14. |
Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7. |
| 15. |
Caksen H, Deda G, Berberoglu M. Does long-term use of valproate cause weight gain in prepubertal epileptic children? Int J Neurosci 2002;112:1183-9. |
| 16. |
Luef G, Abraham I, Haslinger M, Trinka E, Seppi K, Unterberger I, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002;249:835-41. |
| 17. |
Morrell MJ, Isojärvi J, Taylor AE, Dam M, Ayala R, Gomez G, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54:189-99. |
| 18. |
Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28:126-9. |
| 19. |
Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9. |
| 20. |
McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993;270:2207-12. |
| 21. |
Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002;123:882-932. |
| 22. |
Mohamadnejad M, Pourshams A, Malekzadeh R, Mohamadkhani A, Rajabiani A, Asgari AA, et al. Healthy ranges of serum alanine aminotransferase levels in Iranian blood donors. World J Gastroenterol 2003;9:2322-4. |
| 23. |
Hill AJ, Williams J. Psychological health in a non-clinical sample of obese women. Int J Obes Relat Metab Disord 1998;22:578-83. |
| 24. |
Fontaine KR, Cheskin LJ, Barofsky I. Health-related quality of life in obese persons seeking treatment. J Fam Pract 1996;43:265-70. |
| 25. |
Orzano AJ, Scott JG. Diagnosis and treatment of obesity in adults: An applied evidence-based review. J Am Board Fam Pract 2004;17:359-69. |
| 26. |
Schachter SC, Schomer DL, contributors. The Comprehensive Evaluation and Treatment of Epilepsy: A Practical Guide: Illustrated. Son Diego: Academic Press; 1997. p. 53. |
| 27. |
Pylvänen V, Knip M, Pakarinen AJ, Turkka J, Kotila M, Rättyä J, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003;60:571-4. |
| 28. |
Bradly WG. Neurology in Clinical Practice. 4th ed. Tavistock: Butterworth; 2004. p. 1910-1. |
| 29. |
Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253. |
| 30. |
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – The evidence report. National Institutes of Health. Obes Res 1998;6 Suppl 2:51S-209S. |
| 31. |
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. |
| 32. |
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63. |
| 33. |
Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006;8:643-8. |
| 34. |
Azizi F. Tehran lipid and glucose study. Tehran: Endocrine Research Center; 2001. |
| 35. |
Bahrami H, Sadatsafavi M, Pourshams A, Kamangar F, Nouraei M, Semnani S, et al. Obesity and hypertension in an Iranian cohort study; Iranian women experience higher rates of obesity and hypertension than American women. BMC Public Health 2006;6:158. |
| 36. |
Janghorbani M, Amini M, Willett WC, Mehdi Gouya M, Delavari A, Alikhani S, et al. First nationwide survey of prevalence of overweight, underweight, and abdominal obesity in Iranian adults. Obesity (Silver Spring) 2007;15:2797-808. |
| 37. |
VanItallie TB. Prevalence of obesity. Endocrinol Metab Clin North Am 1996;25:887-905. |
| 38. |
Waine C. Nutrition and Physical Activity Task Forces. Obesity. Reversing the Increasing Problem of Obesity in England. London: Department of Health; 1995. |
| 39. |
Rolland-Cachera MF, Cole TJ, Sempe M, Tichet J, Rossignol G, Charraud A. Variations of the body mass index in the French population from 0 to 87 years. In: Obesity in Europe 91. London: John Libbey; 1992. p. 113. |
| 40. |
Seidell JC, Verschuren WM, Kromhout D. Prevalence and trends of obesity in the Netherlands 1987-1991. Int J Obes 1995;19:924-7. |
| 41. |
Pagano R, Lavecchia C. Overweight and obesity in Italy, 1990-91. Int J Obes 1994;18:665-9. |
| 42. |
Malekzadeh R, Mohamadnejad M, Merat S, Pourshams A, Etmadi A. Obesity pandemic: An Iranian perspective. Arch Iran Med 2005;8:1-7. |
| 43. |
Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran lipid and glucose study. Diabetes Res Clin Pract 2003;61:29-37. |
| 44. |
Yumuk VD, Hatemi H, Tarakci T, Uyar N, Turan N, Bagriacik N, et al. High prevalence of obesity and diabetes mellitus in Konya, a central Anatolian city in Turkey. Diabetes Res Clin Pract 2005;70:151-8. |
| 45. |
Erem C, Arslan C, Hacihasanoglu A, Deger O, Topbas M, Ukinc K, et al. Prevalence of obesity and associated risk factors in a Turkish population (Trabzon city, Turkey). Obes Res 2004;12:1117-27. |
| 46. |
Al-Mahroos F, Al-Roomi K. Overweight and obesity in the Arabian Peninsula: An overview. J R Soc Health 1999;119:251-3. |
| 47. |
Al-Malki JS, Al-Jaser MH, Warsy AS. Overweight and obesity in Saudi females of childbearing age. Int J Obes Relat Metab Disord 2003;27:134-9. |
| 48. |
Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB, et al. Obesity in Saudi Arabia. Saudi Med J 2005;26:824-9. |
| 49. |
Kaluski DN, Berry EM. Prevalence of obesity in Israel. Obes Rev 2005;6:115-6. |
| 50. |
Galal OM. The nutrition transition in Egypt: Obesity, undernutrition and the food consumption context. Public Health Nutr 2002;5:141-8. |
| 51. |
Al-Nsour M, Zindah M, Belbeisi A, Hadaddin R, Brown DW, Walke H. Prevalence of selected chronic, non-communicable disease risk factors in Jordan: Results of the Jordan Behavioural Risk Factor Surveillance Survey. Prev Chronic Dis 2012;9:110077. |
| 52. |
Mahmood IH, Mded ZK. Effects of carbamazepine on blood pressure, serum glucose concentration, lipid profile and prevalence of metabolic syndrome in epileptic patients. Tikrit J Pharm Sci 2012;8:2. |
| 53. |
Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, et al. Serum lipid levels in an Iranian adults population: Tehran lipid and glucose study. Eur J Epidemiol 2003;18:311-9. |
| 54. |
Kwan P, Yip FP, Hui AC, Leung H, Ng PW, Hui KF, et al. Effects of valproate or lamotrigine monotherapy on the reproductive endocrine and insulin-related metabolic profile in Chinese adults with epilepsy: A prospective randomized study. Epilepsy Behav 2009;14:610-6. |
| 55. |
Luef G, Abraham I, Hoppichler F, Trinka E, Unterberger I, Bauer G, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:1274-8. |
| 56. |
Tolou-Ghamari Z, Najafi MR, Habibabadi JM, Zare M. Preliminarily analysis of carbamazepine (CBZ) C0 in patients visited Isfahan epileptic clinics. Int J Prev Med 2013;4 Suppl 2:S343-6. |
| 57. |
Najafi MR, Sonbolestan F, Sonbolestan SA, Zare M, Mehvari J, Meshkati SN. The course and outcome of pregnancy and neonatal situation in epileptic women. Adv Biomed Res 2012;1:4.
|
)